Heavy Metal Poisoning

LONDON, Oct. 10, 2023 /PRNewswire/ -- With widespread population expansion and rapid urbanization, the food and accommodation need of human beings have soared dramatically. This leads to the exploitation of environmental or natural resources. Increasing emission levels from vehicles and factors, deforestation, improper waste management, along with other such activities are resulting in a prompt increase in the amount of environmental toxins. These toxins can cause a wide range of diseases in both human beings and animals. Environmental diseases are generally caused when an individual gets excessively exposed to environmental toxins, contaminants, adverse environmental conditions, and pollutants. According to environmental disease statistics 2023 by the Office of Disease Prevention and Health Promotion, over 12 million people lose their lives every year due to such ailments. This has created a need for proper management of such ailments along with stringent measures to regulate pollution levels. The players operating in this landscape are striving to bring about a transformation in the way such ailments are detected, managed, treated, and prevented. They are collaborating with other organizations and government bodies with an aim to accelerate their R&D endeavours and yield fruitful results. Many such players have sought assistance from Disease Landscape Insights due to its deep dive expertise in the field. This health consultant helps them with treatment gaps identification, clinical trial feasibility analysis, overall clinical trial management, product portfolio analysis, and commercial strategy analysis, among others. DLI has also been accelerating the environmental diseases market growth by empowering players with its comprehensive disease insights. Its vast repository encompasses a vast environmental disease pipeline including- Demodex Blepharitis Silicosis Bronchitis Black Lung Disease Emphysema Dermatitis Allergies and Asthma Others Disease Overview- Characteristics, Symptoms, and Triggering Factors Environmental diseases comprise of broad category of health conditions that are primarily caused or exacerbated by exposure to environmental factors. These factors can either be physical, chemical, biological, or a combination thereof. Such ailments mostly result from long-term or repeated exposure and can affect individuals of all ages. The symptoms of environmental diseases can vary depending on the specific condition and the nature of the environmental exposure. Common symptoms may include respiratory problems (e.g., coughing, wheezing), skin disorders (e.g., rashes, irritation), gastrointestinal issues (e.g., nausea, diarrhea), neurological symptoms (e.g., headaches, confusion), and various other health problems. Environmental diseases are triggered or exacerbated by exposure to various environmental hazards. These triggering factors can include air pollution, water contamination, chemical exposure, radiation exposure, occupational hazards, and climate change. Price and Market Access Diagnostic and treatment landscape The early and accurate detection of such diseases play a vital role in safeguarding the lives of the patients. Medical history and physical examination, blood tests, urine tests, x-rays, MRIs, CT scans, allergy testing, biopsies, and environmental monitoring, among others. Environmental diseases market players are taking extensive efforts to develop effective treatment solutions against such ailments. They are striving to cater to environmental disease unmet needs in terms of detection, management, treatment, and prevention. It is worth noting that the treatment plans for such diseases vary depend on their degree of severity and overall health conditions of the patient. Environmental diseases drugs such as bronchodilators and corticosteroids for asthma, antihistamines for allergies, or chelation therapy for heavy metal poisoning are generally recommended by the doctors. Apart from that allergen-specific immunotherapy (allergy shots) are prescribed in case of allergies. Surgical intervention may also be necessary to remove tumors or damaged tissue caused by environmental factors, such as skin cancer or asbestos-related lung disease. Patients may be advised to make lifestyle changes, such as quitting smoking, adopting a healthier diet, or wearing protective clothing, to reduce the impact of environmental factors on their health. DLI has been assisting these players in their drug development endeavours. From offering them with regulatory consulting services, product development services and new product launch services to post launch services, DLI has been a strong support for them. Pharma consulting Services Final Words Environmental diseases have emerged as a global health concern. Growing emission levels, increased air and water pollution rates, deforestation, and rising worldwide population are significantly leading to environmental degradation. Environmental disease epidemiology studies suggest that a significant portion of the world's population gets exposed to harmful environmental toxins every day. This makes them highly susceptible to environmental ailments. Industry players have joined hands to develop effective diagnostic and treatment solutions for this menace. Many of them have opted for pharma consulting services from DLI to solidify their presence in the global market. DLI has been helping them with product portfolio extension, price reimbursement plans, along with clinical trial assessment activities. The management of environmental diseases often involves a multidisciplinary approach, with healthcare providers, environmental specialists, and public health agencies working together to diagnose, treat, and prevent these conditions. The specific treatment plan should be developed in consultation with a healthcare professional, taking into account the individual patient's condition and needs. About Disease Landscape:  Disease Landscape, a pioneering company specializing in Disease Intelligence, Pricing, and Market Access. Utilizing the power of data analytics, Disease Landscape Insights is dedicated to the healthcare sector with invaluable, finely crafted insights and recommendations regarding global pricing and market access strategies. As a specialized firm, we are committed to delivering unparalleled insights into pricing and market access, custom-tailored to the healthcare and pharmaceutical industries. Our data-driven solutions and cutting-edge technology position us as your trustworthy partner, offering swift, adaptable, and evidence-based alternatives to traditional market access and pricing research methods.  Our core competencies encompass Market Research Services, Consulting Services, Global Pricing and Market Access, Epidemiology Studies, as well as Product Portfolio and Pipeline Services. Our expertise lies in furnishing comprehensive data intelligence throughout every phase of drug and device research.  Contact Us:  Disease Landscape Insights LLP  6th Floor, Sr No.207, Office A H 6070 Phase 1  Solitaire Business Hub, Viman Nagar  Pune, Maharashtra, 411014  Email: [email protected]    Email: [email protected] Sales: +44-2038074155  Asia Office: +917447409162 Blog:   Case Study:    Pharma consulting Services  Follow Us: LinkedIn | Twitter | Facebook Logo: SOURCE Disease Landscape Insights

COPENHAGEN, Denmark, Aug. 31, 2023 /PRNewswire/ -- BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, today announces that eight new companies have entered its Venture Lab acceleration program for early-stage companies. The cohort is strategically aligned with BII's focus on supporting innovative early-stage start-ups within human and planetary health. The 12-month Venture Lab program is designed to support start-up companies with business acceleration, scientific, and team development, and provides a founder-friendly convertible loan of EUR 500,000 (approximately 4M DKK) plus access to labs and offices at the BII in Copenhagen. In becoming a part of the Venture Lab program, the early-stage companies also get an exclusive opportunity to apply for EUR 1.3M in follow-up funding through BII's Venture House program. Bobby Soni, Chief Business Officer at BioInnovation Institute, said: "These eight early-stage companies are a fantastic addition to BII's Venture Lab. The start-ups have been selected as they demonstrate great potential to drive the innovation of solutions to current challenges in human and planetary health. We once again look forward to supporting these start-ups by providing our knowledge, network, funding, and infrastructure to build successful companies." Each start-up will be supported in undertaking the necessary steps to reach initial proof-of-concept, to make a business plan and to set up a team. Assisted by a dedicated scientific advisor, a leadership coach and a BII business development expert, the new ventures will be guided in developing a detailed milestone plan and will be assisted in overcoming the challenges of growing a business allowing them to progress rapidly towards the market. The new companies BII has accepted into the Venture Lab acceleration program are: Loma Therapeutics is developing targeted immunotherapy for efficient and safe treatment of patients with HPV infection, dysplasia, and cancer. metaLead is developing revolutionary therapies to treat metal-related diseases, currently focused on Wilson disease, lead poisoning, and neurodegeneration with brain iron accumulation. Leopard Biosciences is democratizing diagnostics by bringing the power of molecular testing to where it's needed most: in the hands of doctors and patients at the point of care. Novozymes' Venture (Corporate Sponsored Project) is exploring how to play a key role to develop and produce at scale cell culture media ingredients for the cultivated meat industry. Amalus Therapeutics is on a mission to profoundly reshape the lives of people affected by cancer and fibrotic diseases. BioHalo is revolutionizing the halogenated chemicals industry by starting with the production of more sustainable and bio-based fluorinated polymers and high-performance materials. Visibuilt is developing an innovative solution for road construction that replaces fossil ingredients in asphalt and reduces energy consumption during production. Rapidemic is developing a molecular point-of-care test for fast and accurate diagnosis of sexually transmitted infections. Since its inception in 2018, BII has supported 87 start-ups and projects with EUR 77 million alongside the venture capital, industry and business expertise it provides to help them accelerate to the next level. In total, BII's start-ups have raised over EUR 424 million in external funding from both local and international investors. Recent company successes include Embark Laboratories, Adcendo, Stipe Therapeutics, Twelve Bio, Octarine Bio, and Cirqle Biomedical. Read more about the Venture Lab program About the BioInnovation Institute Foundation: At BioInnovation Institute (BII), we accelerate world-class life science start-up innovation for the benefit of people and society. As a non-profit institute, BII operates the company creation programs, Bio Studio, Venture Lab and Venture House, to support life science start-ups with knowledge, network, infrastructure and funding of up to 3M EUR per projects and 1,8 M EUR per start-up. With our expertise, network, funding, and infrastructure, we empower startups to succeed and believe in the transformative power of life science innovation. Read more on SOURCE BioInnovation Institute

RECCE® 327 as a gel formulation (R327G) demonstrated a positive clinical response in the treatment of multiple antibiotic-resistant infections under Therapeutic Goods Administration (TGA) Special Access Scheme (SAS) Category A In an ex-vivo burn wound study, R327G showed a 4 to 5-log reduction (>99.99%) against Methicillin-resistant bacteria, Staphylococcus aureus (S. aureus) Clinical trial preparations are underway across multiple unmet medical needs SYDNEY, Australia, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to provide an update on the utilization of RECCE® 327 as a gel formulation, or RECCE® 327 Gel (R327G), by a qualified medical practitioner for patients with antibiotic-resistant Gram-positive and Gram-negative bacterial infections under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS) Category A, a compassionate-use provision. “Antibiotic resistance is globally recognized as one of the greatest threats to human health today,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals. “To see Recce making a difference for patients in such great medical need is a significant sign of new hope in the fight against drug-resistant superbugs. We look forward to building upon these successes in present and future clinical trials.” Patients have been treated under the SAS-Category A, a notification pathway that health practitioners can access on behalf of patients who are seriously ill with a condition from which death is likely to occur within a matter of months or from which premature death is expected to occur in the absence of early treatment and does not constitute a clinical trial.1 R327 and R327G are experimental compounds, not market approved for use in humans, with safety and efficacy to be determined by current clinical studies. The results shown below must be considered anecdotal; however, they are presented in the interest of continuous disclosure obligations and are not part of any current clinical trials. Patient Case Study Example A A 70–75-year-old male who received a puncture wound from a metal spike injury was unresponsive to all prior antibiotics, and with the infection spreading, he was preparing for surgical intervention. After 24 hours and only one dosing application of R327G, the infection had clinically responded, with the patient not requiring a wound debridement prior to treatment. Furthermore, the redness and swelling of the wound were reduced, with no reported stinging at any point. At 30 days post-treatment, the wound had successfully healed and closed. Patient Case Study Example B A 72-year-old male with type 2 diabetes, peripheral vascular disease, and peripheral neuropathy was unresponsive to all prior antibiotics. Prior to treatment with R327G, the patient showed significant bacterial infection, redness, and swelling. Upon applying R327G, the initial redness and swelling had minimized after seven days, with the wound healing and drying up. On day 10, the patient showed no signs of infection and pus formation, and the wound continued to heal. On day 14, the wound significantly improved, demonstrating R327G to be well-tolerated. Surgical intervention was averted, such as limb amputation, which is common in patients with diabetes. Other patient case studies have not been disclosed for matters of confidentiality; however, they include the successful treatment of but are not limited to necrotizing fasciitis (flesh-eating disease), osteomyelitis (bone infection), and complex skin structure bacterial infections. Preclinical results support the potential of R327 as a gel formulation An independent clinical research organization conducted an animal study where multiple R327G formulations were tested for efficacy against Methicillin-resistant S. aureus (MRSA), which is listed as “High” on the World Health Organization’s Priority Pathogen list of antibiotic-resistant bacteria, using an ex-vivo porcine (pig) skin model. R327 as an intravenous (IV) formulation, or R327 IV, was also included in this study and is currently being evaluated in human clinical trials. After 24 hours, R327G achieved a 4 to 5-log reduction (99.99% - 99.999% reduction) in all formulations and had the greatest overall efficacy against MRSA. MRSA infections are one of the leading causes of hospital-acquired infections and are commonly associated with significant morbidity, mortality, length of stay, and cost burden.2 MRSA most often causes skin infections and, if left untreated, can become severe and cause sepsis.3 Treatment Log10 Reduction from Control (Mean ± SD) 1hr Control N/A RECCE® 327 I.V. 3.04 ± 1.20 RECCE® 327 Gel (1.0% CMC) 2.10 ± 1.23 RECCE® 327 Gel (2.0% CMC) 0.90 ± 0.13 24hr Control N/A RECCE® 327 I.V. 4.97 ± 0.11 RECCE® 327 Gel (1.0% CMC) 4.32 ± 0.81 RECCE® 327 Gel (2.0% CMC) 5.07 ± 0.26 Numerical values for Methicillin-resistant Staphylococcus aureus Log10 Reduction The Company engaged Linnaeus Bioscience, based in San Diego, CA, to test R327G against antimicrobial activity in different formulations. The image below shows a clearing in a lawn of Escherichia coli (E. coli) (ATCC 25922) on solid LB-agar media. Each of the gel formulations (R327G “a, b, c and d”) produced a zone of clearing approximately 13mm in diameter, indicating each formulation is active and demonstrates similar potency to R327 IV (B0107) on solid media. Monitored dispersion is observed outside the dark ring. G0001 (placebo control) had no effect on the E. coli; however, R327 IV and R327G successfully dispersed outwards through the bacterial lawn. The above topical results may lead to the progression of R327G to Stage 2 investigations with the burn wound team at Fiona Stanley Hospital, including the potential use among patient populations. Separately, clinical trial applications for the topical utilization of R327G in common and complicated skin and soft tissue infections are progressing in line with these developments. About Recce Pharmaceuticals Ltd Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE® 435 as an orally administered therapy for bacterial infections; and RECCE® 529 for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date. The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE® 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world’s only synthetic polymer and sepsis drug candidate in development. RECCE® 327 is not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy. Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs. Corporate Contact James Graham Recce Pharmaceuticals Ltd +61 (02) 9256 2571 James.graham@recce.com.au Media & Investor Relations (AU) Andrew Geddes CityPR +61 (02) 9267 4511 ageddes@citypublicrelations.com.au Media (USA) Jordyn Temperato LifeSci Communications jtemperato@lifescicomms.com Investor Relations (USA & EU) Guillame van Renterghem LifeSci Advisors gvanrenterghem@lifesciadvisors.com 1 2 3 (MRSA),-Related%20Pages&text=Staph%20bacteria%20are%20usually%20harmless,of%20resistance%20to%20some%20antibiotics. Photos accompanying this announcement are available at Figure 1 Patient Case Study Example A Figure 2 Patient Case Study Example B Figure 3 Clearing in a lawn of Escherichia coli (E. coli) on solid LB-agar media. Table 1 Table 1